Saudi Arabia Concludes Landmark BIO 2025 Debut as Kingdom Opens Doors to Global Biotech Collaboration
BOSTON, June 20, 2025 (GLOBE NEWSWIRE) — Saudi Arabia has concluded its landmark debut at the BIO International Convention 2025, having signed more than a dozen partnerships, launched a national biotech accelerator program with Biolabs and established the Kingdom as a global hub for life sciences. Over four days, Saudi delegates showcased an ecosystem ready for collaboration across scientific discovery, clinical research, and advanced therapeutics.
The Kingdom's presence spanned the entire biotech value chain – from early research to manufacturing, from regulatory frameworks to commercialization pathways.
'Saudi Arabia is stepping into biotech with intention and scale,' said His Excellency the Vice Minister of Health for Planning and Development, Eng. Abdulaziz AlRamaih. 'Biotech sits at the intersection of our health transformation and economic ambition, and we are investing with that dual mandate in mind.'
Partnerships and Programs Take Center Stage
Throughout the week, Saudi Arabia hosted one of the most active national pavilions at the conference, convening more than 25 entities across government, research, investment and innovation. More than a dozen new memoranda of understanding were signed with international partners, including leaders in genomics, AI-enabled diagnostics, gene therapy, and biomanufacturing.
The Ministry of Health also formally launched its national biotech accelerator program in collaboration with BioLabs, welcoming an inaugural cohort of eight Saudi-founded biotech startups in areas ranging from protein engineering to precision genomics. The launch event brought together venture capitalists, researchers, and biotech executives to discuss the Kingdom's innovation momentum.
The Kingdom's Super Session at BIO 2025 featured senior representatives from the Ministry of Health (MoH), the Saudi Food and Drug Authority (SFDA), the Saudi National Institute for Health (SNIH), the King Abdullah International Medical Research Center (KAIMRC), the King Faisal Specialist Hospital and Research Centre (KFSH&RC), and the Public Investment Fund (PIF). The panel revealed how Saudi Arabia is coordinating across policy, clinical infrastructure, and public investment to create a biotech ecosystem built for scale and scientific depth.
In parallel, the delegation held more than 50 one-to-one meetings with global biotech firms and visited U.S. innovation hubs to explore collaboration in research, manufacturing, and translational medicine. The Kingdom also participated in a dedicated gathering for Saudi research talent studying in the United States, underscoring the Kingdom's long-term commitment to human capital in health and life sciences.
Advancing Genomics and Genetic Medicine
The Kingdom's ambition in genomics also drew significant interest. Through the Saudi Genome Program, the Kingdom has developed one of the region's most comprehensive population-specific genomic datasets, paving the way for earlier diagnosis, localized drug development, and new therapeutic approaches for inherited diseases.
National screening efforts – led by Saudi Arabia's Public Health Authority, Weqaya – are expanding access to genetic risk detection through prenatal and newborn programs. Institutions like KFSH&RC and KAIMRC continue to drive forward clinical trials and translational research, supporting a growing pipeline of personalized treatments rooted in real-world data.
Already, over 130 peer-reviewed publications have leveraged Saudi genomic data to inform rare disease research and advance precision diagnostics. The Kingdom's cell and gene therapy readiness now spans regulation, clinical trials, and talent development, with the Saudi Food and Drug Authority's fast-track approval of advanced therapies positioning it as one of the world's most agile regulators.
A Platform for the Future
Under the National Biotechnology Strategy, with the continued support of HRH Prince Mohammed bin Salman, Crown Prince and Prime Minister, Saudi Arabia is making biotech central to its national transformation, and the health and economic prosperity of its people.
The Kingdom concludes BIO 2025 with a clear message: Saudi Arabia is open for collaboration, primed for innovation, and committed to lasting partnerships.
About Saudi Biotech
The Kingdom of Saudi Arabia was proud to debut its first-ever national pavilion at BIO International, being held in Boston June 16-19, 2025. Rooted in Vision 2030, this initiative showcased a fully integrated life sciences ecosystem – combining a future-ready lifestyle, world-class research institutions, streamlined regulation, and digital infrastructure built for speed, scale, and scientific impact. The Kingdom offers a seamless environment for biotech innovation with fast-track clinical trial approvals, robust regulatory alignment via its ML4-designated Food and Drug Authority, and nationwide digital platforms like NPHIES and the world's largest Virtual Hospital.
Saudi Biotech brings together the Kingdom's leading health and science entities, including the Ministry of Health, Saudi Food and Drug Authority, Saudi National Institute of Health, Public Health Authority, and the Saudi Health Council, all of whom play vital roles in enabling a regulatory environment that supports clinical innovation. It also features institutions powering translational research and IP protection, such as the Research, Development and Innovation Authority, King Faisal Specialist Hospital and Research Centre, King Abdulaziz City for Science and Technology, King Abdullah University of Science and Technology, and the King Abdullah International Medical Research Center. Funding and investment facilitators were also present, including the Ministry of Investment, Ministry of Industry and Mineral Resources, and the Saudi Business Center, alongside localization powerhouses like Lifera, Lean, and the Public Investment Fund. Visitors had the opportunity to explore how talent and livability are central to the Kingdom's strategy through participation from the Royal Commission for Riyadh City and the Premium Residency Center. Finally, NEOM showcased the Kingdom's most ambitious vision – a purpose-built frontier for biotech, precision medicine, and future health.
Visit https://www.saudi-biotech.com/ to learn more.
Contact:Saudi Biotech
[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
2 hours ago
- Business Insider
TruGolf Announces Reverse Stock Split
Salt Lake City, Utah, June 18, 2025 (GLOBE NEWSWIRE) -- TruGolf Holdings, Inc. (NASDAQ: TRUG), a leading provider of golf simulator software and hardware, today announced that it filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-50 reverse stock split of its Class A common stock. The reverse stock split will take effect at 12:01 am (Eastern Time) on June 23, 2025, and the Company's Class A common stock will open for trading on The Nasdaq Capital Market on June 23, 2025 on a post-split basis, under the existing ticker symbol 'TRUG' but with a new CUSIP number 243733409. As a result of the reverse stock split, every fifty shares of the Company's Class A common stock issued and outstanding prior to the opening of trading on June 23, 2025 will be consolidated into one issued and outstanding share. Proportionate adjustments will be made to the exercise prices and the number of shares underlying the Company's outstanding equity awards, as applicable, as well as to the number of shares issuable under the Company's equity incentive plans. The Class A common stock issued pursuant to the reverse stock split will remain fully paid and non-assessable. The reverse stock split will not affect the number of authorized shares of Class A common stock or the par value of the Class A common stock. No fractional shares will be issued if, as a result of the reverse stock split, a stockholder would become entitled to a fractional share because the number of shares of Class A common stock they hold before the reverse stock split is not evenly divisible by the split ratio. Instead, the stockholder will be entitled to receive a cash payment in lieu of a fractional share. As a result of the reverse stock split, the number of shares of Class A common stock outstanding will be reduced from approximately 40.5 million shares to approximately 0.8 million shares, and the number of authorized shares of Class A common stock will remain at 650 million shares. About TruGolf, Inc. Since 1983, TruGolf has been passionate about driving the golf industry with innovative indoor golf solutions. TruGolf builds products that capture the spirit of golf. TruGolf's mission is to help grow the game by attempting to make it more Available, Approachable, and Affordable through technology - because TruGolf believes Golf is for Everyone. TruGolf's team has built award-winning video games ("Links"), innovative hardware solutions, and an all-new e-sports platform to connect golfers around the world with E6 CONNECT. Since TruGolf's beginning, TruGolf has continued to attempt to define and redefine what is possible with golf technology. Forward-Looking Statements This news release contains certain statements that constitute 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements that are not of historical fact constitute 'forward-looking statements' and accordingly, involve estimates, assumptions, forecasts, judgements and uncertainties. Forward-looking statements include, without limitation, the timing of the reverse stock split. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors. Any forward-looking statements contained in this release speak only as of its date. The Company undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the SEC, which are available on the SEC's website,
Business Insider
2 hours ago
- Business Insider
TruGolf Announces Acquisition of mlSpatial
Salt Lake City, Utah, June 11, 2025 (GLOBE NEWSWIRE) -- TruGolf Holdings, Inc. (NASDAQ: TRUG), a leading golf technology company, has announced that it has executed a definitive agreement to acquire mlSpatial, a renowned AI and machine learning engineering firm. This strategic acquisition aims to advance the integration of artificial intelligence within TruGolf's industry-leading products, including the Apogee Launch Monitor, Launchbox, Multisport Arcade, and E6 Apex. The collaboration between TruGolf and mlSpatial began in March 2024 with a licensing agreement to co-develop an AI engine enhancing the 9-axis spin accuracy of TruGolf's Apogee Launch Monitor. Building upon this successful partnership, the full acquisition of mlSpatial will enable TruGolf to seamlessly incorporate advanced AI technologies across its entire product suite, delivering unparalleled user experiences, training suggestions, and player insights. 'We are very excited to bring mlSpatial and its AI and machine learning technology into the TruGolf family,' said Chris Jones, TruGolf CEO. He continued, 'Acquiring mlSpatial marks a significant milestone in our commitment to revolutionize golf simulation through cutting-edge AI integration. This acquisition empowers us to explore innovative applications of AI across our ecosystem, enhancing realism and interactivity for our users while lowering development costs.' Josh Pomazal, founder of mlSpatial, expressed enthusiasm about the acquisition: "We're excited to leverage TruGolf's extensive real-time data, collected daily, to continually refine our products with the advanced machine learning and AI models we've developed over the years." This acquisition solidifies our deep commitment to innovation and aligns with the broader industry trend of significant investments in AI infrastructure. Notably, in January 2025, President Donald Trump announced a private-sector initiative, the Stargate Project, aiming to invest up to $500 billion in AI infrastructure within the United States. This substantial investment underscores the rapid progress and importance of AI technologies across various sectors. TruGolf's acquisition of mlSpatial positions the company at the forefront of AI-driven innovation in golf simulation, promising enhanced performance and immersive experiences for enthusiasts worldwide. For more information, please visit About TruGolf Holdings TruGolf is a golf technology company, committed to making golf, easy. From innovative uses for AI to build content and enhance its image and spatial analysis, to gamified golf improvement plans, TruGolf is an industry leader in the growing technological revolution in the sport of golf. Since its founding, TruGolf has redefined what is possible in golf through technology. TruGolf's suite of Hardware, Software, and Web Products make it easier to Play, Improve, and Enjoy the game of golf. Forward-Looking Statements Some of the statements in this release are forward-looking statements, which involve risks and uncertainties. Forward-looking statements include, without limitation, whether the Company's compliance plan will be accepted by Nasdaq and the Company's expected future cash needs. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors. Any forward-looking statements contained in this release speak only as of its date. The Company undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the SEC, which are available on the SEC's website,
Business Upturn
5 hours ago
- Business Upturn
Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA
By GlobeNewswire Published on June 21, 2025, 04:38 IST Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA Results from the phase 3b STEP UP trial showed that a higher dose of Wegovy ® (semaglutide 7.2 mg) delivered 21% weight loss in people with obesity, with a third of participants losing 25% or more of their weight, compared to placebo 1 (semaglutide 7.2 mg) delivered 21% weight loss in people with obesity, with a third of participants losing 25% or more of their weight, compared to placebo Safety and tolerability of the higher dose of Wegovy ® (semaglutide 7.2 mg) was consistent with the currently approved dose (semaglutide 2.4 mg) 1 (semaglutide 7.2 mg) was consistent with the currently approved dose (semaglutide 2.4 mg) The STEP UP data add to the existing evidence base on the value of Wegovy® in delivering significant weight loss and health gains for people living with obesity Bagsværd, Denmark, 21 June 2025 – Novo Nordisk today presented the results from the phase 3b STEP UP trial in people with obesity without diabetes at the American Diabetes Association (ADA) Scientific Sessions, in Chicago, US. In the STEP UP trial, the higher dose of Wegovy® (semaglutide 7.2 mg) demonstrated a mean weight loss of 21%, with a third of participants losing 25% or more of their body weight compared to placebo at 72 weeks.1 'The STEP UP trial demonstrated that we can increase the dose of semaglutide and achieve greater weight loss than previously seen, and in line with semaglutide's established safety profile. This may offer another option to people who do not attain their weight goals,' said Sean Wharton, lead study author and medical director of the Wharton Medical Clinic, Canada. 'We are already aware that semaglutide can have health benefits for people with heart disease, liver disease, knee osteoarthritis, type 2 diabetes and prediabetes. These findings help to give patients with obesity more options for improvements in their weight and overall health.' STEP UP co-primary endpoints at 72 weeks *1 : semaglutide 7.2 mg semaglutide 2.4 mg PlaceboWeight loss 20.7% 17.5% 2.4% 5% or more weight loss 93.2% 92.5% 35.7% When evaluating the effect of treatment regardless of treatment adherence, people receiving semaglutide 7.2 mg achieved 18.7% weight loss vs 3.9% with placebo, and 90.7% achieved 5% or more weight loss with semaglutide 7.2 mg vs 36.8% on placebo. 'With these results, semaglutide reaffirms its significant weight loss for people with obesity. The STEP UP trial delivers a substantial weight loss of over 20%, in addition to health benefits previously demonstrated with semaglutide,' said Ludovic Helfgott, executive vice president of Product & Portfolio Strategy at Novo Nordisk. 'As pioneers in obesity, we continue to develop new innovative treatments to fit the needs and preferences of people living with obesity. This includes maximising the value of semaglutide for individuals, healthcare systems and society, and developing a new oral formulation of Wegovy® that, pending FDA approval, can become the first GLP-1 pill to offer double-digit weight loss.' In the STEP UP trial, semaglutide 7.2 mg demonstrated a well-tolerated safety profile consistent with previous Novo Nordisk semaglutide trials.1 The most common adverse events were gastrointestinal, and the vast majority were mild to moderate during dose escalation and diminished over time, consistent with the GLP-1 class.1 In STEP UP, 3.3% of people treated with semaglutide 7.2 mg discontinued due to gastrointestinal adverse events, compared to 2.0% with semaglutide 2.4 mg and 0% with placebo.1 Novo Nordisk expects to file the higher dose of Wegovy® for a label update in the EU in the second half of 2025, followed by regulatory submissions in other markets where Wegovy® is already approved. STEP UP selected confirmatory secondary endpoints at 72 weeks * 1 : semaglutide 7.2 mg semaglutide 2.4 mg Placebo10% or more weight loss 86.0% 77.6% 20.0%15% or more weight loss 70.4% 57.5% 7.9%20% or more weight loss 50.9% 35.1% 2.9% 25% or more weight loss 33.2% 16.7% 0% * Based on the trial product estimand: treatment effect if all people adhered to treatment. About the STEP UP trials Novo Nordisk has completed two trials, STEP UP and STEP UP T2D, investigating the efficacy and safety of semaglutide 7.2 mg in people with obesity with or without type 2 diabetes. The 72-week STEP UP trial was a randomised, double-blinded, parallel-group, placebo-controlled, superiority trial designed to evaluate the efficacy and safety of semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo as an adjunct to lifestyle intervention. The trial included 1,407 adults with a BMI ≥30 kg/m2 without diabetes. The primary objective was to demonstrate superiority of semaglutide 7.2 mg against placebo on weight loss. Key confirmatory secondary endpoints included the number of participants achieving 10%, 15%, 20% and 25% weight loss, respectively. The 72-week STEP UP T2D trial investigated semaglutide 7.2 mg in 512 adults with obesity and type 2 diabetes, with the primary objective to demonstrate superiority of semaglutide 7.2 mg against placebo on weight loss. About Wegovy® Semaglutide 2.4 mg is marketed under the brand name Wegovy®. In the EU, Wegovy® is indicated as an adjunct to a reduced calorie diet and increased physical activity for weight management in adults with a BMI of 30 kg/m2 or greater (obesity) or adults with a BMI of 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. In the EU, Wegovy® is also indicated for paediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater for age and gender (obesity) and body weight above 60 kg. The clinical section of the label also includes data on Wegovy® major adverse cardiovascular events (MACE) risk reduction, improvements in HFpEF-related symptoms and physical function, as well as pain reduction related to knee osteoarthritis. In the US, Wegovy® is indicated in combination with a reduced calorie diet and increased physical activity to reduce the risk of MACE in adults with established cardiovascular disease and either obesity or overweight, as well as to reduce excess body weight and maintain weight reduction long term in paediatric patients aged 12 years and older with obesity and in adults with obesity or with overweight in the presence of at least one weight-related comorbid condition. About Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. For more information, visit , Facebook , Instagram , X , LinkedIn and YouTube . Contacts for further information References Wharton, S, et al. (2025). Once-weekly semaglutide 7.2 mg in adults with obesity: the randomised, controlled, phase 3b STEP UP trial. 1966-LB poster. American Diabetes Association (ADA) 85th Scientific Sessions, Chicago, US, June 20 – 23, 2025.17. Attachment Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
